Roche CEO Sev­erin Schwan isn’t about to tam­per with a win­ning R&D strat­e­gy now, but he’s still look­ing for ways to cut costs

For years now Roche has dom­i­nat­ed the very top cir­cle of Big Phar­ma R&D, in­vest­ing more than $8 bil­lion a year in drug de­vel­op­ment through a glob­al net­work of re­search cen­ters con­cen­trat­ed at Chugai, gRED in South San Fran­cis­co and pRED out of Basel. And as far as CEO Sev­erin Schwan is con­cerned, that’s a win­ning for­mu­la that he has no plans to tam­per with, even as Roche digs in­to its vast R&D ops in search of some greater ef­fi­cien­cies.

Tim An­der­son

That’s one of the bot­tom lines in an in-depth re­port by Bern­stein an­a­lyst Tim An­der­son af­ter a re­cent sit-down with Schwan, of­fer­ing a chance to do a deep dive in­to the Roche chief’s think­ing on port­fo­lio strat­e­gy, top-line growth and R&D. The dis­cus­sion cen­ters on the CEO’s suc­cess­ful strat­e­gy of gain­ing mar­ket­ing ap­proval for a new set of block­busters like Hem­li­bra as biosim­i­lars bite in­to their ag­ing fran­chise ther­a­pies. 

Roche’s Genen­tech ac­qui­si­tion re­mains one of the most in­trigu­ing M&A suc­cess sto­ries in bio­phar­ma. Genen­tech has con­tin­ued to pro­duce block­buster drugs years af­ter some an­a­lysts would have ex­pect­ed the in­no­v­a­tive juices to have dried up. Schwan at­trib­ut­es their suc­cess to pre­serv­ing their “struc­ture, cul­ture, and in­fra­struc­ture around Genen­tech” while in­te­grat­ing every­thing out­side of R&D. 

So what about an R&D in­te­gra­tion now? “Over my dead body,” replies the CEO. But that doesn’t mean Schwan has stopped look­ing for ways to carve costs out of the re­search and de­vel­op­ment groups.

There are ar­eas where he con­cedes ROG is not very pro­duc­tive, for ex­am­ple, da­ta man­age­ment. ROG is build­ing da­ta sets that share com­mon sys­tems across busi­ness units, where there’s not on­ly an ef­fi­cien­cy el­e­ment, but al­so a pro­duc­tiv­i­ty el­e­ment when you can bet­ter share da­ta. ROG has talked a lot about lever­ag­ing re­al-world da­ta, but it starts with shar­ing your own da­ta from your own clin­i­cal tri­als too. So, they’re do­ing both in par­al­lel.

Back of­fice func­tions and man­u­fac­tur­ing are two key ar­eas where Roche plans to do some cost cut­ting. And their adop­tion of new tri­al de­sign strate­gies al­so of­fers a shot at greater ef­fi­cien­cy.

He thinks de­vel­op­ment is an area where in­tel­li­gent tri­al de­sign can im­prove both ef­fi­cien­cy and pro­duc­tiv­i­ty, lever­ag­ing re­al-world da­ta in a very dif­fer­ent way. Dr. Schwan thinks there’s a lot of po­ten­tial here to in­flu­ence how ROG works with reg­u­la­tors around the world. So, he sees sub­stan­tial pro­duc­tiv­i­ty op­por­tu­ni­ties across the val­ue chain, par­tic­u­lar­ly with­in man­u­fac­tur­ing and de­vel­op­ment.

It’s al­so in­ter­est­ing to see how Schwan sees the com­pa­ny’s po­si­tion in the im­muno-on­col­o­gy field, where he frankly sees Roche be­hind two key lead­ers as Bris­tol-My­ers Squibb and Mer­ck switch places on the num­ber 1 and num­ber 2 po­si­tions. For the CEO, I/O now is on track, with Tecen­triq mak­ing it to the mar­ket in seg­ments of the mar­ket with lim­it­ed op­por­tu­ni­ties. That was the first of three big waves he’s track­ing.

Here’s An­der­son’s sum­ma­ry:

Tecen­triq has pret­ty much achieved what ROG set out to do in this first wave. The sec­ond wave is about com­bi­na­tion strate­gies with Tecen­triq. Dr. Schwan ap­pre­ci­ates the cred­it for chemo com­bo, and we’ve seen that play out well for com­pa­nies that as­cribed to this ap­proach. He ad­mits Keytru­da cer­tain­ly has an ad­van­tage here since they’re al­ready on the mar­ket and ap­proved in 1L lung, and have pos­i­tive re­sults from KN-189 in-hand. ROG is in catch up mode, but still in the race, par­tic­u­lar­ly with IM­pow­er 130, which he views as more com­pa­ra­ble to MRK’s da­ta set. IM­pow­er 150 is a com­plete­ly dif­fer­ent reg­i­men that works bet­ter in cer­tain cas­es than oth­ers. Of course, there’s al­so IM­pow­er 132, which is near-term and very im­por­tant. Yes, Keytru­da is ahead, but de­pend­ing on how var­i­ous tri­als read out, ROG could be back in the game, par­tic­u­lar­ly with IM­pow­er 132. He al­so high­lights the TNBC op­por­tu­ni­ty with Tecen­triq, but views this as a high­er risk ven­ture, rep­re­sent­ing an up­side case. In the third wave of I/O, he thinks the breadth and depth of ROG’s pipeline po­si­tions them as one of, if not, the leader. So, to­day, MRK is no doubt ahead, but he thinks the ju­ry is still out on lung can­cer, and we’ll have to wait and see how the sto­ry with next-gen­er­a­tion nov­el I/O mol­e­cules un­fold.


Im­age: Sev­erin Schwan. ROCHE

Brent Saunders [Getty Photos]

UP­DAT­ED: Ab­b­Vie seals $63B deal to buy a trou­bled Al­ler­gan — spelling out $1B in R&D cuts

Brent Saunders has found his way out of the current fix he’s in at Allergan $AGN. He’s selling the company to AbbVie for $63 billion in the latest example of the hot M&A market in biopharma.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,600+ biopharma pros reading Endpoints daily — and it's free.

Two biotech uni­corns swell pro­posed IPOs, eye­ing a $600M-plus wind­fall

We’ve been wait­ing for the ar­rival of Bridge­Bio’s IPO to top off the wave of new biotech of­fer­ings sweep­ing through Nas­daq at the end of H1. And now we learn that it’s been sub­stan­tial­ly up­sized.

Ini­tial­ly pen­ciled in at a uni­corn-sized $225 mil­lion, the KKR-backed biotech has spiked that to the neigh­bor­hood of $300 mil­lion, look­ing to sell 20 mil­lion shares at $14 to $16 each. That’s an added 5 mil­lion shares, re­ports Re­nais­sance Cap­i­tal, which fig­ures the pro­posed mar­ket val­u­a­tion for Neil Ku­mar’s com­pa­ny at $1.8 bil­lion.

No­var­tis holds back the copy­cat brigade's at­tack on its top drug fran­chise — for now

A fed­er­al judge has put a gener­ic chal­lenge to No­var­tis’ block­buster mul­ti­ple scle­ro­sis drug Gilenya on hold while a patent fight plays out in court.

Judge Leonard P. Stark is­sued a tem­po­rary in­junc­tion ear­li­er this week, forc­ing My­lan, Dr. Red­dy’s Lab­o­ra­to­ries and Au­robindo Phar­ma to shelve their launch plans to al­low the patent fight to pro­ceed. He ruled that al­low­ing the gener­ics in­to the mar­ket now would per­ma­nent­ly slash the price for No­var­tis, even if it pre­vails. 

Af­ter rais­ing $158M, this up­start's founders have star back­ers and plans to break new ground in gene ther­a­py

Back in 2014, Stephanie Tagliatela opted to take an early exit out of her PhD program after working in Mark Bear’s lab at MIT, where she specialized in the synaptic connections between neuronal cells in the brain. She never finished that PhD, but she and fellow MIT student Kartik Ramamoorthi — who was on the founding team at Voyager — came away with some ideas for a gene therapy startup.

Today, fully 5 years later, she and Ramamoorthi are taking the wraps off of a $104 million mega-round designed to take the cumulative work of their preclinical formative stage for Encoded Therapeutics into human studies. They’ve now raised $158 million since starting out in Illumina’s incubator in the Bay Area, and they believe they are firmly on track to do something unique in gene therapy.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,600+ biopharma pros reading Endpoints daily — and it's free.

Sanofi/Re­gen­eron mus­cle ahead of a ri­val No­var­tis/Roche team, win first ap­proval in key rhi­nos­i­nusi­tis field

Re­gen­eron and their part­ners at Sanofi have beat the No­var­tis/Roche team to the punch on an­oth­er key in­di­ca­tion for their block­buster an­ti-in­flam­ma­to­ry drug Dupix­ent. The drug team scored an ac­cel­er­at­ed FDA ap­proval for chron­ic rhi­nos­i­nusi­tis with nasal polyps, mak­ing this the first such NDA for the field.

An­a­lysts have been watch­ing this race for awhile now, as Sanofi/Re­gen­eron won a snap pri­or­i­ty re­view for what is now their third dis­ease in­di­ca­tion for this treat­ment. And they’re not near­ly done, build­ing up hopes for a ma­jor fran­chise.

Novotech CEO Dr. John Moller

Novotech CRO Award­ed Frost & Sul­li­van Best Biotech CRO Asia-Pa­cif­ic 2019

Known in the in­dus­try as the Asia-Pa­cif­ic CRO, Novotech is now lead CRO ser­vices provider for the grow­ing num­ber of in­ter­na­tion­al biotechs se­lect­ing the re­gion for their stud­ies.

Re­flect­ing this Asia-Pa­cif­ic growth, Novotech staff num­bers are up 20% since De­cem­ber 2018 to 600 in-house clin­i­cal re­search peo­ple across a full range of ser­vices, across the re­gion.

Novotech’s ca­pa­bil­i­ties have been rec­og­nized by an­a­lysts like Frost & Sul­li­van, most re­cent­ly with the pres­ti­gious Asia-Pa­cif­ic CRO Biotech of the year award for best prac­tices in clin­i­cal re­search for biotechs for the fifth year. See oth­er awards here.

Top an­a­lyst finds a sil­ver lin­ing in Ab­b­Vie’s $63B Al­ler­gan buy­out — but there’s a catch

Af­ter get­ting beat up on all sides from mar­ket ob­servers who don’t much care for the lat­est mega-deal to ar­rive in bio­phar­ma, at least one promi­nent an­a­lyst now is start­ing to like what he sees in the num­bers for Ab­b­Vie/Al­ler­gan.

But it’s go­ing to take some en­cour­age­ment if Ab­b­Vie ex­ecs want it to last.

Ab­b­Vie’s mar­ket cap de­clined $20 bil­lion on Tues­day as the stock took a 17% hit dur­ing the day. And SVB Leerink’s Ge­of­frey Porges can see a dis­tinct out­line of an up­side af­ter re­view­ing the fun­da­men­tals of the deal.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,600+ biopharma pros reading Endpoints daily — and it's free.

While Ako­rn works to re­vive its for­tunes, the FDA hits it with an­oth­er warn­ing let­ter

Ako­rn just can’t dig it­self out of its hole.

The spe­cial­ty gener­ic drug­mak­er has re­ceived yet an­oth­er warn­ing let­ter from the FDA this year. With­out dis­clos­ing any specifics, the Lake For­est, Illi­nois-based drug­mak­er on Wednes­day said the US reg­u­la­tor had is­sued the let­ter, cit­ing an in­spec­tion of its Som­er­set, New Jer­sey man­u­fac­tur­ing fa­cil­i­ty in Ju­ly and Au­gust of 2018. The com­pa­ny’s shares $AKRX dipped about 1.7% to $4.65 be­fore the bell.

FDA re­jects Ac­er's rare dis­ease drug, asks for new tri­al — shares crater

Ac­er Ther­a­peu­tics’ bid to re­pur­pose celipro­lol — a be­ta-block­er on the mar­ket for hy­per­ten­sion — as a treat­ment for a rare, in­her­it­ed con­nec­tive tis­sue dis­or­der has hit a se­vere set­back. The New­ton, Mass­a­chu­setts-based com­pa­ny on Tues­day said the FDA re­ject­ed the drug and has asked for an­oth­er clin­i­cal tri­al.

The com­pa­ny’s shares $AC­ER cratered near­ly 77% to $4.47 in Tues­day morn­ing trad­ing.